Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy

The number of glioblastoma (GB) cases is increasing every year, and the currently available therapies remain ineffective. A prospective antigen for GB therapy is EGFRvIII, an EGFR deletion mutant containing a unique epitope that is recognized by the L8A4 antibody used in CAR-T (chimeric antigen rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Tręda, Cezary, Włodarczyk, Aneta, Pacholczyk, Marcin, Rutkowska, Adrianna, Stoczyńska-Fidelus, Ewelina, Kierasińska, Amelia, Rieske, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001577/
https://www.ncbi.nlm.nih.gov/pubmed/36901782
http://dx.doi.org/10.3390/ijms24054350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001577/
https://www.ncbi.nlm.nih.gov/pubmed/36901782
http://dx.doi.org/10.3390/ijms24054350

Ejemplares similares